Extravasation of cytotoxic agents;Paravasation von zytostatika

Wiener Klinische Wochenschrift

Volumn 116, Issue 9-10, 2004, Pages 289-295

  Nogler Semenitz, Elisabeth ^a   Mader, Ines ^b   Fürst Weger, Patrizia ^c   Terkola, Robert ^d   Wassertheurer, Sabine ^e   Giovanoli, Pietro ^f   Mader, Robert M ^f  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Austrian Breast/Colorectal C S G   (Austria)

^c SMZ Floridsdorf   (Austria)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e UNIVERSITY HOSPITAL GRAZ   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antineoplastic agents; Extravasation; Prevention; Risk factors; Safety management

Indexed keywords

AMSACRINE; ANTIDOTE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BICARBONATE; BUSULFAN; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DIMETHYL SULFOXIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; HEPARIN; HYALURONIDASE; IDARUBICIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; SODIUM THIOSULFATE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

COOLING; DRUG ANTAGONISM; DRUG CLASSIFICATION; EXTRAVASATION; HUMAN; REVIEW; RISK FACTOR; SAFETY; TISSUE INJURY;

EID: 3042590610     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03040898     Document Type: Review

References (56)

1. Wang JJ, Cortes E, Sinks LF, Holland JF (1971) Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 28: 837-843
2. Rudolph R, Stein SR, Patillo RA (1976) Skin ulcers due to adriamycin. Cancer 39: 1097-1094
3. Bowers DG, Lynch JB (1978) Adriamycin extravasation. Plast Reconstr Surg 61: 86-92
4. Mader I, Fürst-Weger P, Mader R, Semenitz E, Terkola R, Wassertheurer S (2002) Paravasation von Zytostatika. Springer, Wien New York
5. Faehnrich J (1984) Extravasation. NITA 7: 49-52
6. Cox K, Stuart-Harris R, Abdini G, Crygiel J, Raghavan D (1988) The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185-189
7. Hankin FM, Louis DS (1985) Extravasation of chemotherapeutic agents. Am Fam Physician 31: 147-150
8. Köstering H, Nagel GA (1980) Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 6: 317-320
9. Dorr RT (1994) Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer chemotherapy handbook, 2nd edn. Appleton & Lange, pp 109-118
10. Ignoffo RJ, Friedman MA (1980) Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17-27
11. Schneider SM, Distelhorst CW (1989) Chemotherapy-induced emergencies. Semin Oncol 16: 572-578
12. Barth J (2000) Paravasate und deren Behandlung. In: Barth J (Hrsg) Zytostatika-Herstellung in der Apotheke, Kap. VI-3. Deutscher Apotheker Verlag, Stuttgart, S 1-9
13. Stanley A (1997) Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The cytotoxic handbook, 3rd edn. Radcliffe Medical Press, pp 105-124
14. Gain M, Melzer S, Meyer-Jürshof A, Carstens G, Meier K (1997) Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, Melzer S, Meyer-Jürshof A, Carstens G, Meier K (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutischwissenschaftliche Monographien, Bd 1, 2. Aufl. Verlag Heiner Biller, Hamburg, S A42-44
15. Schneider G (1999) Paravasate von Zytostatika. Diagnostik und Therapie, 6. Aufl. Aina S. Schneider Verlag, S 1-17
16. Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41-60
17. Upton J, Mulliken JB, Murray JE (1979) Major intravenous extravasation injuries. Am J Surg 137: 497-506
18. Berdel WE, Schmoll HJ, Büchele T, Dempke W (1999) Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll JH, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie, Teil 1, 3. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 1689-1701
19. Donislawski S, Gain M, Meyer-Jürshof A, Saß G, Carstens G, Meier K (1994) Methotrexat: Behandlung von Paravasaten. In: Donislawski S, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien, Bd 2. Verlag Heiner Biller, Hamburg, S 43
20. Fachinformation Methotrexat "Ebewe" (Österreich). Ebewe, Dezember 1999
21. Bertelli G (1995) Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245-255
22. Fachinformation Bleomycin "Asta Medica" (Österreich), Asta Medica, Jänner 1998
23. Dorr RT, Von Hoff DD (1994) Drug monographs: bleomycin sulfate. In: Dorr RT, Von Hoff DD (eds) Cancer chemotherapy handbook, 2nd edn. Appleton & Lange, pp 227-236
24. Lindner RM, Upton J, Osteen R (1983) Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32-38
25. Montrose PA (1987) Extravasation management. Semin Oncol Nurs 3: 128-132
26. Wetmore N (1985) Extravasation. The dreaded complication. NITA 8: 47-49
27. Linder RM, Upton J, Osteen R (1983) Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32-38
28. San Angel F (1995) Current controversies in chemotherapy administration. J Intraven Nurs 18: 16-23
29. Mullin S, Beckwith MC, Tyler LS (2000) Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57-76
30. Lynch DJ, Key JC, White RR (1979) Management and prevention of infiltration and extravasation injury. Surg Clin North Am 59: 939-949
31. Preuss P, Partoft S (1987) Cytostatic extravasations. Ann Plast Surg 19: 323-327
32. Brown AS, Hoelzer DJ, Piercy SA (1979) Skin necrosis from extravasation of intravenous fluids in children. Plast Reconstr Surg 64: 145-150
33. MacCara ME (1983) Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm 17: 713-717
34. Ayalon A, Anner H, Berlatzky Y, Schiller M (1978) A life-threatening complication of the infusion pump. Lancet 1: 853-854
35. Barlock AL, Howser DM, Hubbard SM (1979) Nursing management of adriamycin extravasation. Am J Nurs 79: 94-96
36. Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796-1799
37. Harwood KV, Aisner J (1984) Treatment of chemotherapy extravasafion: current status. Cancer Treat Rep 68: 939-945
38. Lane P, Vichi P, Bain DL, Tritton TR (1987) Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res 47: 4038-4042
39. Dorr RT, Alberts DS, Stone A (1985) Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 69: 431-437
40. David NA (1972) The pharmacology of dimethylsulfoxide 6544. Ann Rev Pharmacol 12: 353-374
41. Kligman AM (1965) Topical pharmacology and toxicology of dimethyl sulfoxide - part I. JAMA 193: 796-804
42. Görög P, Kovács IB (1969) Effect of dimethylsulfoxide (DMSO) on various experimental cutaneous reactions. Pharmacology 2: 313-319
43. Desai MH, Teres D (1982) Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep 66: 1371-1374
44. Massart C, Le Tellier C, Gibassier J, Leclech G, Nicol M (1993) Modulation by dimethyl sulphoxide of the toxicity induced by cis-diamminedichloroplatinum in cultured thyrocytes. Toxicol in vitro 7: 87-94
45. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851-2855
46. Bertelli G, Dini D, Fomo GB, Gozza A, Silvestro S, Venturini M, et al (1994) Hyaluronidase as an antidote to extravasation of vinca alcaloids: clinical results. J Cancer Res Clin Oncol 120: 505-506
47. Goodman M, Stewart I, Lydon J, Blendowski C, Barnicle M, Petersen J, et al (1996) Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum 3: 541-542
48. Jackson IT, Robinson DW (1976) Severe tissue damage following accidental subcutaneous infusion of bicarbonat solution. Scot Med J 21: 200-201
49. Gaze NR (1978) Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417-419
50. Krämer I (1992) Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154-160
51. Dorr RT, Alberts DS (1985) Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74: 113-120
52. Rudolph R (1978) Ulcers of the hand and wrist caused by doxorubicin hydrochloride. Orthop Rev 7: 93-95
53. Luedke DW, Kennedy PS, Rietschel RL (1979) Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Texonstr Surg 63: 463-465
54. Rudolph R, Larson DL (1987) Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5: 1116-1126
55. Köstering H, Kasten U, Ruskowski H, Beyer J-H, Nagel GA (1981) Lokale Toxizität des Adriamycins. In: Eckhardt S, Holzner JH, Nagel GA (Hrsg) Beiträge zur Onkologie, Bd 9. Karger, Basel, S 756-793
56. Krämer I (2002) Zehn Jahre Dokumenation von Zytostatika-Paravasat- Ereignissen. Krankenhauspharmazie 23: 269-274